SVB Wealth LLC Sells 9,904 Shares of Abbott Laboratories $ABT

SVB Wealth LLC trimmed its position in Abbott Laboratories (NYSE:ABT) by 16.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,977 shares of the healthcare product maker’s stock after selling 9,904 shares during the period. SVB Wealth LLC’s holdings in Abbott Laboratories were worth $5,336,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. American National Bank of Texas grew its position in shares of Abbott Laboratories by 2.4% in the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after buying an additional 79 shares during the period. Nia Impact Advisors LLC lifted its position in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares during the period. Park Place Capital Corp boosted its stake in Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after acquiring an additional 81 shares in the last quarter. Lantern Wealth Advisors LLC grew its holdings in Abbott Laboratories by 1.7% in the third quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock worth $674,000 after purchasing an additional 84 shares during the period. Finally, Clayton Financial Group LLC increased its stake in shares of Abbott Laboratories by 1.4% during the fourth quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock valued at $779,000 after purchasing an additional 84 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the topic of a number of analyst reports. Stifel Nicolaus dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Mizuho reduced their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein lowered their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. UBS Group cut their target price on Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Finally, BTIG Research restated a “buy” rating and set a $131.00 price target on shares of Abbott Laboratories in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.30.

Abbott Laboratories Price Performance

Shares of ABT opened at $87.78 on Tuesday. The company has a market capitalization of $152.90 billion, a P/E ratio of 24.59, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm has a 50 day moving average of $89.78 and a 200 day moving average of $106.18. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the firm posted $1.09 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.